(2-Hydroxy-3,4,5,6-tetraphosphonooxycyclohexyl) phosphono hydrogen phosphate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2-Hydroxy-3,4,5,6-tetraphosphonooxycyclohexyl) phosphono hydrogen phosphate
• 化学式: C₆H₁₈O₂₄P₆
• 分子量: 660.04
• InChiKey: RLQGQDJUKRAXDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -10.3
• 重原子数：
  36
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  401
• 氢给体数：
  12
• 氢受体数：
  24

文献信息

• DRUG SCREENING SYSTEMS AND ASSAYS
  申请人：Cancer Research Technology Limited

  公开号：EP1283903A1

  公开（公告）日：2003-02-19
• METHODS OF PREDICTING AND DECREASING THE RISK OF PRE-TERM BIRTH
  申请人：University Of Louisville Research Foundation, Inc.

  公开号：EP2756302A1

  公开（公告）日：2014-07-23
• [EN] DRUG SCREENING SYSTEMS AND ASSAYS<br/>[FR] SYSTEMES ET METHODES DE CRIBLAGE DE MEDICAMENTS
  申请人：IMP CANCER RES TECH

  公开号：WO2001090404A1

  公开（公告）日：2001-11-29

  A method of stimulating non-homologous end-joining (NHEJ) of DNA the method comprising performing NHEJ of DNA in the presence of inositol hexakisphosphate (IP6) or other stimulatory inositol phosphate. An assay of a protein kinase wherein the assay comprises inositol hexakisphosphate (IP6) or other stimulatory inositol phosphate. The invention also provides screening assays for compounds which may modulate NHEJ and which may be therapeutically useful; and screening assays for compounds which may modulate DNA-PK and related protein kinases and which may be therapeutically useful. Methods of modulating NHEJ and protein kinases are also disclosed.
• [EN] METHODS OF PREDICTING AND DECREASING THE RISK OF PRE-TERM BIRTH<br/>[FR] PROCÉDÉS DE PRÉDICTION ET DE DIMINUTION DU RISQUE D'UNE NAISSANCE PRÉMATURÉE
  申请人：UNIV LOUISVILLE RES FOUND

  公开号：WO2013040211A1

  公开（公告）日：2013-03-21

  Provided are methods for predicting the risk of pre-term birth in a pregnant subject, for identifying a subject having an increased risk of pre-term birth, for selecting a subject for participation in a clinical study, and for decreasing the risk of pre-term birth in a subject. These methods include providing a sample from the subject and detecting the level of one or more of growth arrest-specific protein 1 (GASI), ALLI-fused gene from chromosome 4 protein (AR4)/Fragile X Mental Retardation 2 (FMR2) family member 3 (AFF3), transthyretin (TTR), ryanodine receptor 1 (RYRI), E26 transformation specific variant 6 (ETV6), claudin-10, zinc finger protein 23 (ZNF23), collagen type XXVII al (COL27AI), Kazrin isoform-1, keratin-associated protein 10-9 (KRTAPIO-9), Huntingtin (HTT), microtubule associated protein 9 (MAP9), coiled-coil domain-containing protein 13 (CCDC13), inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase isoform 2 (HISPPDI), immunoglobulin gamma-3 chain C (IGHG3), cysteine- and histidine-rich protein-1 (CYHRI ), and XP 002348181.